CDKN2A and central nervous system cancer: Although CDKN2A deletion is well known to be a poor prognostic factor in low-grade diffuse gliomas with IDH mutations, the present study showed that it is also a poor prognostic factor in higher-grade gliomas that acts as a more important prognostic factor than IDH mutation, especially in CNS WHO grade 4 gliomas.